Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients
Autore:
Jeste, DV; Lacro, JP; Bailey, A; Rockwell, E; Harris, MJ; Caligiuri, MP;
Indirizzi:
UnivsychiatSan Diego, Vet Affairs San Diego Healthcare Syst 116A, Geriatr P Univ Calif San Diego San Diego CA USA 92161 althcare Syst 116A, Geriatr P
Titolo Testata:
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
fascicolo: 6, volume: 47, anno: 1999,
pagine: 716 - 719
SICI:
0002-8614(199906)47:6<716:LIOTDW>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Keywords:
psychosis; neuroleptics; movement disorder; aging; dementia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Jeste, DV UnivsychiatSango,ego, Vet Affairs San Diego Healthcare Syst 116A, Geriatr P Univ Calif San Diego 3350 La Jolla Village Dr San Diego CA USA 92161
Citazione:
D.V. Jeste et al., "Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients", J AM GER SO, 47(6), 1999, pp. 716-719

Abstract

OBJECTIVE: To compare the 9-month cumulative incidence of tardive dyskinesia (TD) with risperidone to that with haloperidol in older patients. DESIGN: A prospective longitudinal study. SETTING: An outpatient psychiatric clinic. PARTICIPANTS: Subjects were middle-aged and older (mean age 66 years) patients with schizophrenia, dementia, mood disorders, or other conditions withpsychotic symptoms or severe behavioral disturbances. Sixty-one patients on risperidone were matched with 61 patients from a larger sample of haloperidol-treated patients in regard to age, diagnosis, and length of preenrollment neuroleptic intake to create clinically comparable groups. The median daily dose of each medication was 1.0 mg. MEASUREMENTS: Abnormal Involuntary Movement Scale, modified Simpson-Angus'scale for extrapyramidal symptoms, Brief Psychiatric Rating Scale, and Mini-Mental State Examination were administered at baseline, 1 month, and 3, 6, and 9 months. The diagnosis of TD was based on specific research criteria. The raters were blind to the patient's medication status. RESULTS: Life table analysis revealed that patients treated with haloperidol were significantly more likely to develop TD than patients treated with risperidone (P < .05, Peto-Prentice). CONCLUSIONS: The atypical antipsychotic risperidone is significantly less likely to result in TD than the conventional neuroleptic haloperidol in a high-risk group of older patients, at least over a 9-month period.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 19:03:29